RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for ¹⁸F-FDG of 17 July 2018.

Fludeoxyglucose (¹⁸F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.

Other news

1st production QuiremSpheres

On May 21st, the first patient dosis of QuiremSpheres was processed at RTM and then shipped to the s...

LinkedIn post ESRR2024

📢 Important update on EU #GMP Annex 1 at #ESRR2024!  The revised EU GMP Annex 1, effecti...

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

First Patient Dosed with TLX250-CDx in Italy for ccRCC

The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...

News